Ironwood Pharma (IRWD) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update
May 1, 2018 7:55 AM EDTFirst quarter revenue increased 33% year-over-year to $69 million, driven primarily by LINZESS® (linaclotide) U.S. net sales of $159 million and commercial margin of 63%
IW-3718 Phase III program expected to initiate in the third quarter of 2018
Phase II sGC programs, praliciguat and olinciguat (IW-1701) continue to progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ:... More
